Ripasudil

• Description:

  Ripasudil (K-115) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively.

• Product Name Alternative:

  K-115

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  ROCK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/K-115.html

• Purity:

  99.95

• Solubility:

  DMSO : 25 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

• Smiles:

  FC1=CN=CC2=C1C (S (N3CCCNC[C@@H]3C) (=O) =O) =CC=C2.[H]Cl.O.O

• Molecular Formula:

  C15H23ClFN3O4S

• Molecular Weight:

  395.88

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Isobe T, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014 Aug;39 (8) :813-22.|[2]Kaneko Y, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells. Sci Rep. 2016 Jan 19;6:19640.|[3]Yamamoto K, et al. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci. 2014 Oct 2;55 (11) :7126-36.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  ROCK1; ROCK2

• Citation 01:

  Curr Eye Res. 2023 Sep;48 (9) :826-835.|Exp Eye Res. 2024 Jun 18:109977.|Mol Ther. 2023 Jun 7;31 (6) :1846-1856.|Preprints. 2023 May 15.|Science. 2017 Dec 1;358 (6367) :eaan4368.|Adv Sci (Weinh) . 2022 May;9 (13) :e2104682.

• CAS Number:

  887375-67-9